Beyond Air (XAIR)
(Delayed Data from NSDQ)
$0.38 USD
0.00 (0.08%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $0.38 0.00 (1.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
Beyond Air, Inc. [XAIR]
Reports for Purchase
Showing records 1 - 20 ( 56 total )
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
We are updating our Healthcare coverage to reflect a recent analyst departure and to drop
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
FY2Q23 Recap - Launch in Progress; Cardiac Indication a Differentiator
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Our Inaugural Healthcare Opportunities Conference in New York City on October 6th
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
FY1Q23 - Launch Underway; Cardiac Indication Could Add to Differentiation
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
FY4Q22 Recap - Approval In Hand; Launch Imminent
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S